Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2007071646) NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2007/071646 International Application No.: PCT/EP2006/069830
Publication Date: 28.06.2007 International Filing Date: 18.12.2006
IPC:
C07D 241/20 (2006.01) ,C07D 403/10 (2006.01) ,A61K 31/497 (2006.01) ,A61P 31/18 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
241
Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
02
not condensed with other rings
10
having three double bonds between ring members or between ring members and non-ring members
14
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
20
Nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965
Non-condensed pyrazines
497
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
18
for HIV
Applicants:
ANDRÉS-GIL, José, Ignacio [ES/ES]; ES (UsOnly)
ALCÁZAR-VACA, Manuel, Jesús [ES/ES]; ES (UsOnly)
ÁLVAREZ-ESCOBAR, Rosa, María [ES/ES]; ES (UsOnly)
OYARZABAL SANTAMARINA, Julen [ES/ES]; ES (UsOnly)
DAUTZENBERG, Frank, Matthias [DE/BE]; BE (UsOnly)
MACRITCHIE, Jacqueline [GB/GB]; GB (UsOnly)
SIMPSON, Donald [GB/GB]; GB (UsOnly)
MARTINEZ GONZALEZ, Sonia [ES/ES]; ES (UsOnly)
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30 B-2340 Beerse, BE (AllExceptUS)
Inventors:
ANDRÉS-GIL, José, Ignacio; ES
ALCÁZAR-VACA, Manuel, Jesús; ES
ÁLVAREZ-ESCOBAR, Rosa, María; ES
OYARZABAL SANTAMARINA, Julen; ES
DAUTZENBERG, Frank, Matthias; BE
MACRITCHIE, Jacqueline; GB
SIMPSON, Donald; GB
MARTINEZ GONZALEZ, Sonia; ES
Common
Representative:
JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30 B-2340 Beerse, BE
Priority Data:
05112616.721.12.2005EP
Title (EN) NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES
(FR) NOUVEAUX DERIVES DE PYRAZINONE SUBSTITUEE A UTILISER LORS DE MALADIES MEDIEES PAR MCH-1
Abstract:
(EN) The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-I activity according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereo chemically isomeric form thereof, an TV-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders ; obesity ; diabetes ; sexual disorders and neurological disorders.
(FR) L'invention concerne des dérivés de pyrazinone substituée par aryle et hétéroaryle présentant une activité d'hormone de concentration en mélanine (MCH) antagoniste, en particulier une activité de MCH-1 selon la formule générale (I), un sel d'addition d'acide ou de base, une forme stéréo-chimiquement isomère, une forme de N-oxyde ou un sel d'ammonium quaternaire de ceux-ci pharmaceutiquement acceptable, dont les paramètres sont définis dans la Revendication 1. L'invention concerne en outre la préparation de ces dérivés, les compositions les renfermant et leur utilisation comme médicament. Les composés selon l'invention servent à prévenir et/ou à traiter des troubles psychiatriques, notamment l'anxiété, les troubles de l'alimentation, les troubles de l'humeur, par exemple les troubles bipolaires et la dépression, les psychoses, par exemple la schizophrénie, et les troubles du sommeil; l'obésité; les diabètes; les troubles sexuels et les troubles neurologiques.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)